

2026 ICD-10 Code Updates

Overview of New ICD-10-CM Effective FY 2026

Disclaimer:

This presentation is intended for educational purposes only and is accurate as of the time of development.

While every effort has been made to ensure accuracy, errors or omissions may exist.

Please confirm the guidelines, official instructions, and payer-specific requirements that would take precedence over this material.

Always:

Verify codes with the current ICD-10-CM code set and official guidelines.

Remember to keep your compliance hat on.

Query your provider.

The presenter assumes no responsibility or liability for coding decisions based on this material.

Again, this presentation is intended for educational purposes only.

No part of this presentation or the corresponding handouts may be reproduced or shared without the consent of MedCycle Solutions.

Why the 2026 Updates Matter

Improved clinical specificity

Reflects current medical knowledge

Supports accurate reimbursement

ICD-10-CM Diagnosis Code Changes

Hundreds of new diagnosis codes added

Expanded injury, ulcer, and chronic condition coding

New remission and social determinant codes

Impact on Providers and Coders

More detailed documentation required

Improved data accuracy

Reduced claim denials when applied correctly

Implementation Tips

Review updated coding guidelines

Train staff on new codes

Update EHR and coding tools, such as your EMR chargemaster

2026 Update Timeline

Effective October 1, 2025

Applies through September 30, 2026

487 new codes

38 revised codes (other revisions such as punctuation)

28 deleted codes

Guideline changes...

1.A.7 page G3

, Commas are used in the Alphabetic Index and have different meanings based on the context of the Index entry, including alternate verbiage, modifier (essential and nonessential), or alternative for “and/or.”

Chapter Highlights...

Chapter 1: Certain Infectious and Parasitic Diseases (A00-B99)

New codes for Demodex mite infestation, with corresponding blepharitis codes

Guideline update: Enhanced clarification for HIV sequencing

Code	Description
B88.01	Infestation by Demodex mites
B88.09	Other acariasis

Revised:

Code	Description	Date/Notes
B88.0	Other acariasis	9/30/2025 B88.0 has been expanded into B88.0 Other acariasis

1.C.1.a.2... page G7

Selection and sequencing in HIV codes

(a) *HIV disease*

If the term “AIDS” or “HIV disease” is documented or if the patient is treated for any HIV-related illness or is described as having any condition(s) resulting from the patient’s HIV positive status; code B20, Human immunodeficiency virus [HIV], should be assigned.

(b) Patient admitted for HIV-related condition

If a patient is admitted for an HIV-related condition, the principal diagnosis should be B20, Human immunodeficiency virus [HIV] disease followed by additional diagnosis codes for all reported HIV-related conditions.

An exception to this guideline is if the reason for admission is hemolytic-uremic syndrome associated with HIV disease. Assign code D59.31, Infection-associated hemolytic-uremic syndrome, followed by code B20, Human immunodeficiency virus [HIV] disease.

(c) Patient with HIV disease admitted for unrelated condition

If a patient with HIV disease is admitted for an unrelated condition (such as a traumatic injury), the code for the unrelated condition (e.g., the nature of injury code) should be the principal diagnosis. Code B20 would be reported as a secondary diagnosis. Codes for other documented conditions should also be reported as secondary diagnoses.

(d) *Patient newly diagnosed with HIV disease*

Whether the patient is newly diagnosed or has had previous admissions/encounters for HIV conditions is irrelevant to the sequencing decision.

(e) **Asymptomatic human immunodeficiency virus**

When “HIV positive,” “HIV test positive,” or similar terminology is documented, and there is no documentation of symptoms or HIV-related illness, code Z21, Asymptomatic human immunodeficiency virus [HIV] infection status, should be assigned.

(f) *Inconclusive HIV serology*

Patients with documentation of inconclusive HIV serology, may be assigned code R75, Inconclusive laboratory evidence of human immunodeficiency virus [HIV].

(g) **Previously diagnosed HIV-related illness**

Patients with documentation of a prior diagnosis of an HIV-related illness should be coded to B20. Once an HIV-related illness has developed, code B20 should always be assigned on every subsequent admission/encounter. Patients previously diagnosed with any HIV illness (B20) should never be assigned to R75, Inconclusive laboratory evidence of human immunodeficiency virus [HIV] or Z21, Asymptomatic human immunodeficiency virus [HIV] infection status.

(h) HIV Infection in Pregnancy, Childbirth and the Puerperium

When a patient presents during pregnancy, childbirth or the puerperium with documented symptomatic HIV disease or an HIV related illness, assign a code from subcategory O98.7, Human immunodeficiency [HIV] disease complicating pregnancy, childbirth and the puerperium, followed by code B20 and additional code(s) for any HIV-related illness(es). Codes from Chapter 15 always take sequencing priority.

When a patient presents during pregnancy, childbirth or the puerperium with documented asymptomatic HIV infection status or is HIV-positive, assign a code from subcategory O98.7 followed by code Z21.

(i) *Encounters for HIV testing*

If a patient without signs or symptoms is tested for HIV, assign code Z11.4, Encounter for screening for human immunodeficiency virus [HIV]. Use additional codes for any associated high-risk behavior, if applicable.

If a patient with signs or symptoms of HIV presents for HIV testing, code the signs and symptoms. An additional counseling code Z71.7, Human immunodeficiency virus [HIV] counseling, may be assigned if counseling is provided during the encounter for the test. Code Z11.4, Encounter for screening for human immunodeficiency virus [HIV], should not be assigned if HIV signs or symptoms are present.

When a patient presents for follow up regarding their HIV test results and the test result is negative, assign code Z71.7, Human immunodeficiency virus [HIV] counseling.

(j) *HIV disease or HIV positive status managed by antiretroviral medication*

If a patient with documented HIV disease, HIV-related illness or AIDS is currently managed on antiretroviral medications, assign code B20, Human immunodeficiency virus [HIV] disease.

If a patient with documented HIV positive status is currently managed on antiretroviral medication, assign code Z21, Asymptomatic human immunodeficiency virus [HIV] infection status, in the absence of any additional documentation of HIV disease, HIV-related illness or AIDS.

Code Z79.899, Other long term (current) drug therapy, may be assigned as an additional code to identify the long-term (current) use of antiretroviral medications.

(k) *Encounter for HIV Prophylaxis Measures*

When a patient presents for administration of pre-exposure prophylaxis medication for HIV, assign code Z29.81, Encounter for HIV pre-exposure prophylaxis. Pre-exposure prophylaxis (PrEP) is intended to prevent infection in people who are at risk for getting HIV through sex or injection drug use. Any risk factors for HIV should also be coded.

Chapter 2: Neoplasms (C00 – D49)

Added codes for inflammatory breast cancer, improving classification of aggressive malignancies

Minor guidance updates for antineoplastic treatment coding

Code	Description
C50.A0	Malignant inflammatory neoplasm of unspecified breast
C50.A1	Malignant inflammatory neoplasm of right breast
C50.A2	Malignant inflammatory neoplasm of left breast

1.C.2.e.2...page G11

2) Patient admission/encounter chiefly for administration of antineoplastic chemotherapy, immunotherapy and radiation therapy

If a patient admission/encounter is chiefly for the administration of chemotherapy, immunotherapy or external beam radiation therapy **for the treatment of a neoplasm**, assign code Z51.0, Encounter for antineoplastic radiation therapy, or Z51.11, Encounter for antineoplastic chemotherapy, or Z51.12, Encounter for antineoplastic immunotherapy as the first-listed or principal diagnosis. **If the reason for the encounter is more than one type of antineoplastic therapy, code Z51.0 and codes from subcategory Z51.1 may be assigned together, in which case one of these codes would be reported as a secondary diagnosis.**

The malignancy for which the therapy is being administered should be assigned as a secondary diagnosis.

If a patient admission/encounter is for the insertion or implantation of radioactive elements (e.g., brachytherapy) the appropriate code for the malignancy is sequenced as the principal or first-listed diagnosis. Code Z51.0 should not be assigned.

Chapter 3: Blood and Immune Disorders (D50 – D89)

New codes for leukocyte adhesion deficiency, a rare genetic disorder impacting immune function

Code	Description
D71.1	Leukocyte adhesion deficiency
D71.8	Other functional disorders of polymorphonuclear neutrophils
D71.9	Functional disorders of polymorphonuclear neutrophils, unspecified

Revised:

Code	Description	Date/Notes
		9/30/2025 D71 has been expanded into D71 Functional disorders of polymorphonuclear neutrophils
D71	Functional disorders of polymorphonuclear neutrophils	

Chapter 4: Endocrine, Nutritional, and Metabolic Diseases (E00 – E89)

Introduction of a code for type 2 diabetes in remission

New codes to indicate distinct types of nutritional and metabolic disorders

Guideline revision: Clear criteria for coding remission status, enhancing risk adjustment accuracy

Code	Description
E11.A	Type 2 diabetes mellitus without complications in remission
E72.530	Primary hyperoxaluria, type 1
E72.538	Other specified primary hyperoxaluria
E72.539	Primary hyperoxaluria, unspecified
E72.540	Dietary hyperoxaluria
E72.541	Enteric hyperoxaluria
E72.548	Other secondary hyperoxaluria
E72.549	Secondary hyperoxaluria, unspecified
E78.010	Homozygous familial hypercholesterolemia [HoFH]
E78.011	Heterozygous familial hypercholesterolemia [HeFH]
E78.019	Familial hypercholesterolemia, unspecified
E83.820	Generalized arterial calcification of infancy with unspecified genetic causality
E83.821	ENPP1 deficiency causing generalized arterial calcification of infancy
E83.822	ENPP1 deficiency causing autosomal recessive hypophosphatemic rickets type 2
E83.823	ABCC6 deficiency causing generalized arterial calcification of infancy
E83.824	ABCC6 deficiency causing pseudoxanthoma elasticum
E83.825	CD73 deficiency causing arterial calcification
E88.10	Lipodystrophy, unspecified
E88.11	Partial lipodystrophy
E88.12	Generalized lipodystrophy
E88.13	Localized lipodystrophy
E88.14	HIV-associated lipodystrophy
E88.19	Other lipodystrophy, not elsewhere classified

Chapter 4: Endocrine, Nutritional, and Metabolic Diseases (E00 – E89)

Expanded:

Code	Description	Date/Notes
E72.53	Primary hyperoxaluria	9/30/2025 E72.53 has been expanded into E72.53 Primary hyperoxaluria
E78.01	Familial hypercholesterolemia	9/30/2025 E78.01 has been expanded into E78.01 Familial hypercholesterolemia
E88.1	Lipodystrophy, not elsewhere classified	9/30/2025 E88.1 has been expanded into E88.1 Lipodystrophy, not elsewhere classified

1.C.4.a.1.b ... page G12

(b) Type 2 diabetes mellitus in remission

Code E11.A, Type 2 diabetes mellitus without complications in remission, is assigned based on provider documentation that the diabetes mellitus is in remission. If the documentation is unclear as to whether the Type 2 diabetes mellitus has achieved remission, the provider should be queried. For example, the term “resolved” is not synonymous with remission.

Chapter 5: Mental, Behavioral and Neurodevelopmental Disorders (F01 – F99)

No changes for 2026

Chapter 6: Diseases of the Nervous System (G00 – G99)

Added codes for primary progressive apraxia of speech, multiple sclerosis subtypes, and muscular dystrophy variants

Code	Description
G31.87	Primary progressive apraxia of speech
G35.A	Relapsing-remitting multiple sclerosis
G35.B0	Primary progressive multiple sclerosis, unspecified
G35.B1	Active primary progressive multiple sclerosis
G35.B2	Non-active primary progressive multiple sclerosis
G35.C0	Secondary progressive multiple sclerosis, unspecified
G35.C1	Active secondary progressive multiple sclerosis
G35.C2	Non-active secondary progressive multiple sclerosis
G35.D	Multiple sclerosis, unspecified
G71.036	Limb girdle muscular dystrophy due to fukutin related protein dysfunction

Revised:

Code	Description	Date/Notes
G35	Multiple sclerosis	9/30/2025 G35 has been expanded into G35 Multiple sclerosis

Chapter 7: Eye and Adnexa (H00 – H59)

Expansion of blepharitis codes, including Demodex-related diagnoses
New codes for thyroid eye disease and neovascular glaucoma

Code	Description
H01.81	Other specified inflammation of right upper eyelid
H01.82	Other specified inflammation of right lower eyelid
H01.83	Other specified inflammation of right eye, unspecified eyelid
H01.84	Other specified inflammation of left upper eyelid
H01.85	Other specified inflammation of left lower eyelid
H01.86	Other specified inflammation of left eye, unspecified eyelid
H01.89	Other specified inflammation of unspecified eye, unspecified eyelid
H01.8A	Other specified inflammation of right eye, upper and lower eyelids
H01.8B	Other specified inflammation of left eye, upper and lower eyelids
H05.831	Thyroid orbitopathy, right orbit
H05.832	Thyroid orbitopathy, left orbit
H05.833	Thyroid orbitopathy, bilateral
H05.839	Thyroid orbitopathy, unspecified orbit
H40.841	Neovascular secondary angle closure glaucoma, right eye
H40.842	Neovascular secondary angle closure glaucoma, left eye
H40.843	Neovascular secondary angle closure glaucoma, bilateral
H40.849	Neovascular secondary angle closure glaucoma, unspecified eye

Chapter 8: Diseases of the Ear and Mastoid Process (H60 – H95)

No changes for 2026

Chapter 9: Diseases of the Circulatory System (I00 – I99)

4 new codes for Fontan circulation

Guideline revision: Clarifies sequencing for hypertension with heart disease and chronic kidney disease

Code	Description
I27.840	Fontan-associated liver disease [FALD]
I27.841	Fontan-associated lymphatic dysfunction
I27.848	Other Fontan-associated condition
I27.849	Fontan related circulation, unspecified

1.C.9.a.1... page G17

1) **Hypertension with Heart Disease**

Hypertension with heart conditions **classified to I50.-, Heart failure, I51.4, Myocarditis, unspecified, I51.89, Other ill-defined heart diseases, and I51.9, Heart disease, unspecified,** is assigned to a code from category I11, Hypertensive heart disease. Use additional code(s) from category I50, Heart failure, or I51, Complications and ill-defined descriptions of heart disease, to identify the heart condition.

Hypertension with heart conditions classified to I51.5, Myocardial degeneration, or I51.7, Cardiomegaly, is assigned to a code from category I11, Hypertensive heart disease. No additional code is assigned to identify the specific heart condition.

The same heart conditions (I50.-, I51.4-I51.7, I51.89, I51.9) with hypertension are coded separately if the provider has documented they are unrelated to the hypertension. **The applicable hypertension code I10, Essential (primary) hypertension, or a code from category I15, Secondary hypertension, should be assigned.** Sequence according to the circumstances of the admission/encounter.

Chapter 10: Diseases of the Respiratory System (J00 – J99)

No changes for 2026

Chapter 11: Diseases of the Digestive System (K00 – K95)

No changes for 2026

Chapter 12: Diseases of the Skin and Subcutaneous Tissue (L00 – L99)

Chapter 12 features one of the most substantial updates, introducing >100 new codes for non-pressure chronic ulcers, now classified by anatomical site and severity

Code	Description
L02.217	Cutaneous abscess of flank
L02.227	Furuncle of flank
L03.31A	Cellulitis of flank
L03.32A	Acute lymphangitis of flank

Chapter 12: Diseases of the Skin and Subcutaneous Tissue (L00 – L99)

New:

Code	Description
L98.43__	Non-pressure chronic ulcer of abdomen _____
L98.44__	Non-pressure chronic ulcer of chest _____
L98.45__	Non-pressure chronic ulcer of neck _____
L98.46__	Non-pressure chronic ulcer of face _____
L98.47__	Non-pressure chronic ulcer of groin _____
L98.A11__	Non-pressure chronic ulcer of right upper arm _____
L98.A12__	Non-pressure chronic ulcer of left upper arm _____
L98.A19__	Non-pressure chronic ulcer of unspecified upper arm _____
L98.A21__	Non-pressure chronic ulcer of right forearm _____
L98.A22__	Non-pressure chronic ulcer of left forearm _____
L98.A29__	Non-pressure chronic ulcer of unspecified forearm _____
L98.A31__	Non-pressure chronic ulcer of right hand _____
L98.A3__	Non-pressure chronic ulcer of left hand _____
L98.A391	Non-pressure chronic ulcer of unspecified hand _____

7th characters:

1	limited to breakdown of skin	5	with muscle involvement without evidence of necrosis
2	with fat layer exposed	6	with bone involvement without evidence of necrosis
3	with necrosis of muscle	7	with other specified severity
4	with necrosis of bone	8	with unspecified severity

Chapter 13: Diseases of the Musculoskeletal and Connective Tissue (M00 – M99)

Additional code for abnormal rheumatoid factor

New guidance on documenting multiple anatomical sites and applying chapter-specific rules

Code	Description
M05.A	Abnormal rheumatoid factor and anti-citrullinated protein antibody with rheumatoid arthritis

1.B.20... page G7

20. ***Multiple Sites Coding***

The classification defines “multiple” as involving two or more sites. Follow chapter-specific guidelines for assigning codes for “multiple sites.” In the absence of chapter-specific guidelines, assign codes describing specified sites individually when documented. When the specified site(s) are not documented, assign the appropriate code for “multiple sites.”

Chapter 14: Diseases of the Genitourinary System (N400 – N99)

New codes for *APOL1*-mediated kidney disease, as well as genetic susceptibility and family history indicators

Code	Description
N00.B1	Acute nephritic syndrome with idiopathic immune membranoproliferative glomerulonephritis (IC-MPGN)
N00.B2	Acute nephritic syndrome with secondary immune complex membranoproliferative glomerulonephritis (IC-MPGN)
N04.B1	Nephrotic syndrome with idiopathic immune complex membranoproliferative glomerulonephritis (IC-MPGN)
N04.B2	Nephrotic syndrome with secondary immune complex membranoproliferative glomerulonephritis (IC-MPGN)
N07.B	Hereditary nephropathy, not elsewhere classified with APOL1-mediated kidney disease [AMKD]

Chapter 15: Pregnancy, Childbirth, and the Puerperium (000 – 09A)

No changes for 2026

Chapter 16: Certain Conditions Originating in the Perinatal Period (P00 – P96)

No changes for 2026

Chapter 17: Congenital Malformations, deformations, and chromosomal abnormalities (Q00 – Q99)

23 new codes for genetic syndromes and neurodevelopmental disorders tied to specific pathogenic variants

A new subsection for neurodevelopmental coding

Code	Description
Q87.87	Hao-Fountain Syndrome
Q87.88	CTNNB1 syndrome
Q89.81	Kabuki syndrome
Q89.89	Other specified congenital malformations
Q99.811	Usher syndrome, type 1
Q99.812	Usher syndrome, type 2
Q99.813	Usher syndrome, type 3
Q99.818	Other Usher syndrome
Q99.819	Usher syndrome, unspecified
Q99.89	Other specified chromosome abnormalities
QA0.0101	SCN2A-related neurodevelopmental disorder
QA0.0102	CACNA1A-related neurodevelopmental disorder
QA0.0109	Neurodevelopmental disorder related to pathogenic variant in other ion channel gene
QA0.011	Neurodevelopmental disorders, related to pathogenic variants in glutamate receptor genes
QA0.012	Neurodevelopmental disorders, related to pathogenic variants in other receptor genes
QA0.0131	SLC6A1-related disorder
QA0.0139	Neurodevelopmental disorder, related to pathogenic variant in other transporter or solute carrier gene
QA0.0141	Syntaxin-binding protein 1-related disorder
QA0.0142	DLG4-related synaptopathy
QA0.0149	Neurodevelopmental disorder, related to pathogenic variant in other synapse related gene
QA0.0151	FOXP1 syndrome
QA0.0159	Neurodevelopmental disorder, related to other genes associated with transcription and gene expression
QA0.8	Other neurodevelopmental disorders related to pathogenic variants in other specific genes

Chapter 17: Congenital Malformations, deformations, and chromosomal abnormalities (Q00 – Q99)

Expanded:

Code	Description	Date/Notes
Q89.8	Other specified congenital malformations	9/30/2025 Q89.8 has been expanded into Q89.8 Other specified congenital malformations
Q99.8	Other specified chromosome abnormalities	9/30/2025 Q99.8 has been expanded into Q99.8 Other specified chromosome abnormalities

Chapter 18: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00 – R99)

New codes for:

- Flank pain

- Cannabis hyperemesis syndrome

- Immunologic abnormalities (e.g., abnormal serum findings)

Code	Description
R10.20	Pelvic and perineal pain unspecified side
R10.21	Pelvic and perineal pain right side
R10.22	Pelvic and perineal pain left side
R10.23	Pelvic and perineal pain bilateral
R10.24	Suprapubic pain
R10.85	Abdominal pain of multiple sites
R10.8A1	Right flank tenderness
R10.8A2	Left flank tenderness
R10.8A3	Suprapubic tenderness
R10.8A9	Flank tenderness, unspecified
R10.A0	Flank pain, unspecified side
R10.A1	Flank pain, right side
R10.A2	Flank pain, left side
R10.A3	Flank pain, bilateral
R11.16	Cannabis hyperemesis syndrome
R39.851	Costovertebral (angle) tenderness, right side
R39.852	Costovertebral (angle) tenderness, left side
R39.853	Costovertebral (angle) tenderness, bilateral
R39.859	Costovertebral (angle) tenderness, unspecified side
R76.81	Abnormal rheumatoid factor and anti-citrullinated protein antibody without rheumatoid arthritis
R76.89	Other specified abnormal immunological findings in serum

Expanded:

Code	Description	Date/Notes
R10.2	Pelvic and perineal pain	9/30/2025 R10.2 has been expanded into R10.2 Pelvic and perineal pain
R76.8	Other specified abnormal immunological findings in serum	9/30/2025 R76.8 has been expanded into R76.8 Other specified abnormal immunological findings in serum

Chapter 19: Injury, Poisoning and Other Consequences of External Causes (S00 – T88)

213 new codes, including:

- Specific flank injuries (e.g., contusions, lacerations)

- New poisonings (e.g., fluoroquinolones, xylazine)

- Blast injuries and anaphylaxis from specific triggers

Chapter 19: Injury, poisoning, and certain other consequences of external causes (S00-T88)



New	
S30.11_	Contusion of abdominal wall, _____
S30.12_	Contusion of groin, _____
S30.13_	Contusion of flank (latus) region, _____
S30.81A_	Abrasion of flank, _____
S30.82A_	Blister (nonthermal) of flank, _____
S30.84A_	External constriction of flank, _____
S30.85A_	Superficial foreign body of flank, _____
S30.86A_	Insect bite (nonvenomous) of flank, _____
S30.87A_	Other superficial bite of flank, _____
S30.9AX_	Unspecified superficial injury of flank, _____

A	Initial encounter	D	Subsequent Encounter	S	Sequela
----------	-------------------	----------	----------------------	----------	---------

Deleted:

Code	Description	Date/Notes
S30.1XXA	Contusion of abdominal wall, initial encounter	9/30/2025 Code Deleted.
S30.1XXD	Contusion of abdominal wall, subsequent encounter	9/30/2025 Code Deleted.
S30.1XXS	Contusion of abdominal wall, sequela	9/30/2025 Code Deleted.

Chapter 19: Injury, poisoning, and certain other consequences of external causes (S00-T88)

New	
S31.106_	Unspecified open wound of abdominal wall, right flank without penetration into peritoneal cavity, ____
S31.107_	Unspecified open wound of abdominal wall, left flank without penetration into peritoneal cavity, ____
S31.10A_	Unspecified open wound of abdominal wall, unspecified flank without penetration into peritoneal cavity, ____
S31.116_	Laceration without foreign body of abdominal wall, right flank without penetration into peritoneal cavity, ____
S31.117_	Laceration without foreign body of abdominal wall, left flank without penetration into peritoneal cavity, ____
S31.11A_	Laceration w/o foreign body of abdominal wall, unspecified flank without penetration into peritoneal cavity, ____
S31.126_	Laceration with foreign body of abdominal wall, right flank without penetration into peritoneal cavity, ____
S31.127_	Laceration with foreign body of abdominal wall, left flank without penetration into peritoneal cavity, ____
S31.12A_	Laceration with foreign body of abdominal wall unspecified flank without penetration into peritoneal cavity, ____

A	Initial encounter	D	Subsequent Encounter	S	Sequela
----------	-------------------	----------	----------------------	----------	---------

Chapter 19: Injury, poisoning, and certain other consequences of external causes (S00-T88)

New	
S31.136_	Puncture wound of abdominal wall w/o foreign body, right flank w/o penetration into peritoneal cavity, ___
S31.137_	Puncture wound of abdominal wall w/o foreign body, left flank w/o penetration into peritoneal cavity, ___
S31.13A_	Puncture wound of abdominal wall w/o foreign body, unspecified flank w/o penetration into peritoneal cavity, ___
S31.146_	Puncture wound of abdominal wall with foreign body, right flank w/o penetration into peritoneal cavity, ___
S31.147_	Puncture wound of abdominal wall with foreign body, left flank w/o penetration into peritoneal cavity, ___
S31.14A_	Puncture wound of abdominal wall with foreign body, unspecified flank w/o penetration into peritoneal cavity, ___
S31.156_	Open bite of abdominal wall, right flank w/o penetration into peritoneal cavity, _____
S31.157_	Open bite of abdominal wall, left flank w/o penetration into peritoneal cavity, _____
S31.15A_	Open bite of abdominal wall, unspecified flank w/o penetration into peritoneal cavity, _____

A	Initial encounter	D	Subsequent Encounter	S	Sequela
----------	-------------------	----------	----------------------	----------	---------

Chapter 19: Injury, poisoning, and certain other consequences of external causes (S00-T88)

New	
S31.606_	Unspecified open wound of abdominal wall, right flank with penetration into peritoneal cavity, ____
S31.607_	Unspecified open wound of abdominal wall, left flank with penetration into peritoneal cavity, ____
S31.60A_	Unspecified open wound of abdominal wall, unspecified flank with penetration into peritoneal cavity, ____
S31.616_	Laceration without foreign body of abdominal wall, right flank with penetration into peritoneal cavity, ____
S31.617_	Laceration without foreign body of abdominal wall, left flank with penetration into peritoneal cavity, ____
S31.61A_	Laceration without foreign body of abdominal wall, unspecified flank with penetration into peritoneal cavity, ____
S31.626_	Laceration with foreign body of abdominal wall, right flank with penetration into peritoneal cavity, ____
S31.627_	Laceration with foreign body of abdominal wall, left flank with penetration into peritoneal cavity, ____
S31.62A_	Laceration with foreign body of abdominal wall, unspecified flank with penetration into peritoneal cavity, ____

A	Initial encounter	D	Subsequent Encounter	S	Sequela
----------	-------------------	----------	----------------------	----------	---------

Chapter 19: Injury, poisoning, and certain other consequences of external causes (S00-T88)

New	
S31.636_	Puncture wound of abdominal wall w/o foreign body, right flank with penetration into peritoneal cavity, ____
S31.637_	Puncture wound of abdominal wall w/o foreign body, left flank with penetration into peritoneal cavity, ____
S31.63A_	Puncture wound of abdominal wall w/o foreign body, unspecified flank with penetration into peritoneal cavity, __
S31.646_	Puncture wound of abdominal wall with foreign body, right flank with penetration into peritoneal cavity, ____
S31.647_	Puncture wound of abdominal wall with foreign body, left flank with penetration into peritoneal cavity, ____
S31.64A_	Puncture wound of abdominal wall with foreign body, unspecified flank with penetration into peritoneal cavity, __
S31.656_	Open bite of abdominal wall, right flank with penetration into peritoneal cavity, ____
S31.657_	Open bite of abdominal wall, left flank with penetration into peritoneal cavity, ____
S31.65A_	Open bite of abdominal wall, unspecified flank with penetration into peritoneal cavity, ____

A	Initial encounter	D	Subsequent Encounter	S	Sequela
----------	-------------------	----------	----------------------	----------	---------

Fluoroquinolone

Code	Description
T36.AX1A	Poisoning by fluoroquinolone antibiotics, accidental (unintentional), initial encounter
T36.AX1D	Poisoning by fluoroquinolone antibiotics, accidental (unintentional), subsequent encounter
T36.AX1S	Poisoning by fluoroquinolone antibiotics, accidental (unintentional), sequela
T36.AX2A	Poisoning by fluoroquinolone antibiotics, intentional self-harm, initial encounter
T36.AX2D	Poisoning by fluoroquinolone antibiotics, intentional self-harm, subsequent encounter
T36.AX2S	Poisoning by fluoroquinolone antibiotics, intentional self-harm, sequela
T36.AX3A	Poisoning by fluoroquinolone antibiotics, assault, initial encounter
T36.AX3D	Poisoning by fluoroquinolone antibiotics, assault, subsequent encounter
T36.AX3S	Poisoning by fluoroquinolone antibiotics, assault, sequela
T36.AX4A	Poisoning by fluoroquinolone antibiotics, undetermined, initial encounter
T36.AX4D	Poisoning by fluoroquinolone antibiotics, undetermined, subsequent encounter
T36.AX4S	Poisoning by fluoroquinolone antibiotics, undetermined, sequela
T36.AX5A	Adverse effect of fluoroquinolone antibiotics, initial encounter
T36.AX5D	Adverse effect of fluoroquinolone antibiotics, subsequent encounter
T36.AX5S	Adverse effect of fluoroquinolone antibiotics, sequela
T36.AX6A	Underdosing of fluoroquinolone antibiotics, initial encounter
T36.AX6D	Underdosing of fluoroquinolone antibiotics, subsequent encounter
T36.AX6S	Underdosing of fluoroquinolone antibiotics, sequela

Xylazine

Code	Description
T65.841A	Toxic effect of xylazine, accidental (unintentional), initial encounter
T65.841D	Toxic effect of xylazine, accidental (unintentional), subsequent encounter
T65.841S	Toxic effect of xylazine, accidental (unintentional), sequela
T65.842A	Toxic effect of xylazine, intentional self-harm, initial encounter
T65.842D	Toxic effect of xylazine, intentional self-harm, subsequent encounter
T65.842S	Toxic effect of xylazine, intentional self-harm, sequela
T65.843A	Toxic effect of xylazine, assault, initial encounter
T65.843D	Toxic effect of xylazine, assault, subsequent encounter
T65.843S	Toxic effect of xylazine, assault, sequela
T65.844A	Toxic effect of xylazine, undetermined, initial encounter
T65.844D	Toxic effect of xylazine, undetermined, subsequent encounter
T65.844S	Toxic effect of xylazine, undetermined, sequela

Gulf War Illness

Code	Description
T75.830A	Gulf war illness, initial encounter
T75.830D	Gulf war illness, subsequent encounter
T75.830S	Gulf war illness, sequela
T75.838A	Effects of other war theater, initial encounter
T75.838D	Effects of other war theater, subsequent encounter
T75.838S	Effects of other war theater, sequela

Blast overpressure

Code	Description
Y36.A1XA	Low level blast overpressure in war operations, initial encounter
Y36.A1XD	Low level blast overpressure in war operations, subsequent encounter
Y36.A1XS	Low level blast overpressure in war operations, sequela
Y36.A2XA	High level blast overpressure in war operations, initial encounter
Y36.A2XD	High level blast overpressure in war operations, subsequent encounter
Y36.A2XS	High level blast overpressure in war operations, sequela
Y37.A1XA	Low level blast overpressure in military operations, initial encounter
Y37.A1XD	Low level blast overpressure in military operations, subsequent encounter
Y37.A1XS	Low level blast overpressure in military operations, sequela
Y37.A2XA	High level blast overpressure in military operations, initial encounter
Y37.A2XD	High level blast overpressure in military operations, subsequent encounter
Y37.A2XS	High level blast overpressure in military operations, sequela

Baked Milk/Baked Egg

Code	Description
T78.070A	Anaphylactic reaction due to milk and dairy products with tolerance to baked milk, initial encounter
T78.070D	Anaphylactic reaction due to milk and dairy products with tolerance to baked milk, subsequent encounter
T78.070S	Anaphylactic reaction due to milk and dairy products with tolerance to baked milk, sequela
T78.071A	Anaphylactic reaction due to milk and dairy products with reactivity to baked milk, initial encounter
T78.071D	Anaphylactic reaction due to milk and dairy products with reactivity to baked milk, subsequent encounter
T78.071S	Anaphylactic reaction due to milk and dairy products with reactivity to baked milk, sequela
T78.079A	Anaphylactic reaction due to milk and dairy products, unspecified, initial encounter
T78.079D	Anaphylactic reaction due to milk and dairy products, unspecified, subsequent encounter
T78.079S	Anaphylactic reaction due to milk and dairy products, unspecified, sequela
Code	Description
T78.080A	Anaphylactic reaction due to egg with tolerance to baked egg, initial encounter
T78.080D	Anaphylactic reaction due to egg with tolerance to baked egg, subsequent encounter
T78.080S	Anaphylactic reaction due to egg with tolerance to baked egg, sequela
T78.081A	Anaphylactic reaction due to egg with reactivity to baked egg, initial encounter
T78.081D	Anaphylactic reaction due to egg with reactivity to baked egg, subsequent encounter
T78.081S	Anaphylactic reaction due to egg with reactivity to baked egg, sequela
T78.089A	Anaphylactic reaction due to eggs, unspecified, initial encounter
T78.089D	Anaphylactic reaction due to eggs, unspecified, subsequent encounter
T78.089S	Anaphylactic reaction due to eggs, unspecified, sequela

Baked Milk/Baked Egg

Code	Description
T78.110A	Other adverse food reactions due to milk and dairy products with tolerance to baked milk, initial encounter
T78.110D	Other adverse food reactions due to milk and dairy products with tolerance to baked milk, subsequent encounter
T78.110S	Other adverse food reactions due to milk and dairy products with tolerance to baked milk, sequela
T78.111A	Other adverse food reaction due to milk and dairy products with reactivity to baked milk, initial encounter
T78.111D	Other adverse food reaction due to milk and dairy products with reactivity to baked milk, subsequent encounter
T78.111S	Other adverse food reaction due to milk and dairy products with reactivity to baked milk, sequela
T78.119A	Other adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, initial encounter
T78.119D	Other adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, subsequent encounter
T78.119S	Other adverse food reaction due to milk and dairy products with baked milk tolerance/reactivity, unspecified, sequela
Code	Description
T78.120A	Other adverse food reaction due to egg with tolerance to baked egg, initial encounter
T78.120D	Other adverse food reaction due to egg with tolerance to baked egg, subsequent encounter
T78.120S	Other adverse food reaction due to egg with tolerance to baked egg, sequela
T78.121A	Other adverse food reaction due to egg with reactivity to baked egg, initial encounter
T78.121D	Other adverse food reaction due to egg with reactivity to baked egg, subsequent encounter
T78.121S	Other adverse food reaction due to egg with reactivity to baked egg, sequela
T78.129A	Other adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, initial encounter
T78.129D	Other adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, subsequent encounter
T78.129S	Other adverse food reaction due to egg with baked egg tolerance/reactivity, unspecified, sequela

Milk/Eggs Deletions

Code	Description	Date/Notes
T78.07XA	Anaphylactic reaction due to milk and dairy products, initial encounter	9/30/2025 Code Deleted.
T78.07XD	Anaphylactic reaction due to milk and dairy products, subsequent encounter	9/30/2025 Code Deleted.
T78.07XS	Anaphylactic reaction due to milk and dairy products, sequela	9/30/2025 Code Deleted.
T78.08XA	Anaphylactic reaction due to eggs, initial encounter	9/30/2025 Code Deleted.
T78.08XD	Anaphylactic reaction due to eggs, subsequent encounter	9/30/2025 Code Deleted.
T78.08XS	Anaphylactic reaction due to eggs, sequela	9/30/2025 Code Deleted.
T78.1XXA	Other adverse food reactions, not elsewhere classified, initial encounter	9/30/2025 Code Deleted.
T78.1XXD	Other adverse food reactions, not elsewhere classified, subsequent encounter	9/30/2025 Code Deleted.
T78.1XXS	Other adverse food reactions, not elsewhere classified, sequela	9/30/2025 Code Deleted.

Additional Adverse Reactions:

Code	Description
T78.19XA	Other adverse food reactions, not elsewhere classified, initial encounter
T78.19XD	Other adverse food reactions, not elsewhere classified, subsequent encounter
T78.19XS	Other adverse food reactions, not elsewhere classified, sequela

Expanded:

Code	Description	Date/Notes
Z40.8	Encounter for other prophylactic surgery	9/30/2025 Z40.8 has been expanded into Z40.8 Encounter for other prophylactic surgery
Z59.86	Financial insecurity	9/30/2025 Z59.86 has been expanded into Z59.86 Financial insecurity
Z84.1	Family history of disorders of kidney and ureter	9/30/2025 Z84.1 has been expanded into Z84.1 Family history of disorders of kidney and ureter
Z91.011	Allergy to milk products	9/30/2025 Z91.011 has been expanded into Z91.011 Allergy to milk products
Z91.012	Allergy to eggs	9/30/2025 Z91.012 has been expanded into Z91.012 Allergy to eggs

Chapter 19: Injury, poisoning, and certain other consequences of external causes (S00-T88)

Revised (new description)

S62.90X_	Unspecified fracture of unspecified hand, _____
S62.91X_	Unspecified fracture of right hand _____
S62.92X_	Unspecified fracture of left hand _____

Revised (previous description)

S62.90X_	Unspecified fracture of unspecified wrist and hand _____
S62.91X_	Unspecified fracture of right wrist and hand _____
S62.92X_	Unspecified fracture of left wrist and hand _____

A	Initial encounter for closed fracture	B	Initial encounter for open fracture	D	Subsequent encounter for fracture with routine healing
G	Subsequent encounter for fracture with delayed healing	K	Subsequent encounter for fracture with nonunion	P	Subsequent encounter for fracture with malunion
S	Sequela				

Chapter 20: External Causes of Morbidity (V00 – Y99)

Expanded external cause codes for:

- Fishing hook injuries

- Splitting wood

- Blast overpressure from military or war-related events

Code	Description
W44.H9XA	Other sharp object entering into or through a natural orifice, initial encounter
W44.H9XD	Other sharp object entering into or through a natural orifice, subsequent encounter
W44.H9XS	Other sharp object entering into or through a natural orifice, sequela
W45.3XXA	Fishing hook entering through skin, initial encounter
W45.3XXD	Fishing hook entering through skin, subsequent encounter
W45.3XXS	Fishing hook entering through skin, sequela
Code	Description
Y93.L1	Activity, splitting wood
Y93.L9	Activity, other outdoor activity

Chapter 21: Factors influencing health status and contact with health services (Z00 – Z99)

26 new codes, including:

- Prophylactic salpingectomy

- DES (Diethylstilbestrol) exposure

- Social determinants of health, such as utility insecurity, food and housing instability, and exposure to adverse environmental conditions

Code	Description
Z15.05	Genetic susceptibility to malignant neoplasm of fallopian tube(s)
Z15.060	Genetic susceptibility to colorectal cancer
Z15.068	Genetic susceptibility to other malignant neoplasm of digestive system
Z15.07	Genetic susceptibility to malignant neoplasm of urinary tract
Z15.3	Genetic susceptibility to kidney disease

Code	Description
Z40.81	Encounter for prophylactic surgery for removal of ovary(s) for persons without known genetic/familial risk factors
Z40.82	Encounter for prophylactic surgery for removal of fallopian tube(s) for persons without known genetic/familial risk factors
Z40.89	Encounter for other prophylactic surgery

Code	Description
Z59.861	Financial insecurity, difficulty paying for utilities
Z59.868	Other specified financial insecurity
Z59.869	Financial insecurity, unspecified

Code	Description
Z77.31	Contact with and (suspected) exposure to Gulf War theater
Z77.39	Contact with and (suspected) exposure to other war theater

Code	Description
Z80.44	Family history of malignant neoplasm of fallopian tube(s)
Z84.11	Family history of APOL1-mediated kidney disease [AMKD]
Z84.19	Family history of other disorders of kidney and ureter
Z84.A	Family history of exposure to diethylstilbestrol

Code	Description
Z91.B	Personal risk factor of exposure to diethylstilbestrol

Chapter 22: Codes for Special Purposes (U00 – U85)

No new codes for 2026

Resources

[CMS ICD-10 Updates Page](#)

[2026 ICD-10-CM Code Files](#)

[FY 2026 Official Guidelines PDF](#)

In conclusion...

Documentation is key.

Continue to encourage clinicians to provide such things as:

- Laterality

- Location

- Severity

- Cause

- Personal/Familial History

- Social Determinants of Health

Questions & Discussion

Thank you

Questions?